zirconium has been researched along with everolimus in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
de Jong, S; de Vries, EG; Kosterink, JG; Lub-de Hooge, MN; Pot, L; Reyners, AK; Schröder, CP; Terwisscha van Scheltinga, AG; Timmer-Bosscha, H; van der Bilt, AR; van der Zee, AG | 1 |
Bongaerts, AH; Brouwers, AH; de Jong, JR; de Vries, EG; Fiebrich, HB; Links, TP; Lub-de Hooge, MN; Oosting, SF; Oude Munnink, TH; Sluiter, WJ; van Asselt, SJ; Walenkamp, AM | 1 |
2 other study(ies) available for zirconium and everolimus
Article | Year |
---|---|
Measurement of tumor VEGF-A levels with 89Zr-bevacizumab PET as an early biomarker for the antiangiogenic effect of everolimus treatment in an ovarian cancer xenograft model.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Bevacizumab; Biomarkers, Tumor; Cell Line, Tumor; Everolimus; Female; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Ovarian Neoplasms; Positron-Emission Tomography; Radioisotopes; Radiopharmaceuticals; Sirolimus; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays; Zirconium | 2012 |
Everolimus Reduces (89)Zr-Bevacizumab Tumor Uptake in Patients with Neuroendocrine Tumors.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Bevacizumab; Biological Transport; Chromogranin A; Everolimus; Feasibility Studies; Female; Humans; Male; Middle Aged; Neuroendocrine Tumors; Positron-Emission Tomography; Radioisotopes; Sirolimus; Treatment Outcome; Vascular Endothelial Growth Factor A; Zirconium | 2014 |